Janssen Archives - Page 5 of 6 - Medical Design Sourcing

J&J’s Tremfya shows promise in psoriatic arthritis patients who are TNFi non-responders

The Janssen division of Johnson & Johnson (NYSE:JNJ) has announced that its selective IL-23 inhibitor Tremfya (guselkumab) led to joint symptom improvement and skin clearance in the majority of patients with an inadequate response to tumor necrosis factor inhibitors (TNFi’s).

After 24 weeks of treatment, 44.4% of patients who received Tremfya had at least a 20% improvement in joint symptoms using the American College of Rheumatology’s ACR20 scale, which requires at least a 20% improvement in several arthritis measures. Some 19.9% of placebo recipients had the same degree of improvement.

At one year, 57.7% achieved more than 20% improvement in joint symptoms using the American College of Rheumatology’s ACR20 scale, which requires at least a 20% improvement in several arthritis measures. Some 53.4% of the psoriatic arthritis patients had complete skin clearance.

“We’re basically continuing to develop the body of evidence to help physicians make d…

U.K. authorizes J&J COVID-19 vaccine

The United Kingdom announced that it approved the single-dose COVID-19 vaccine developed by Johnson & Johnson’s Janssen Pharmaceutical business.

The Medicines and Healthcare products Regulatory Agency (MHRA) granted the regulatory approval, making Janssen’s the fourth COVID-19 vaccine authorized by the independent regulator and the first to be approved as a single-dose option, according to a news release.

Read: 9 things to know as AstraZeneca and J&J COVID-19 vaccines face safety scrutiny

Approval gives authorization to the use of the vaccine in people aged 18 years old and above in the UK, the MHRA said, while the decision on use of the vaccine in pregnant or breastfeeding women should be made in consultation with a healthcare professional after considering the benefits and risks, the regulatory body said.

“We have undertaken a thorough review of the conditional marketing authorization applica…

House report accuses AbbVie of price gouging

A recent report from the House Oversight and Reform Committee concluded that AbbVie (NYSE:ABBV) aggressively increased prices of popular drugs, including the bestseller Humira (adalimumab), which brought in close to $20 billion last year. Approximately $16 billion of those sales were in the U.S.

In recent years, the company also repeatedly increased the price of the small-molecule drug Imbruvica (ibrutinib), according to the report, which is the result of a two-year investigation. AbbVie jointly markets Imbruvica with Janssen (NYSE:JNJ).

An annual supply of Humira costs approximately $77,000, while a year’s worth of Imbruvica is $181,529, according to the House report. The price of the latter has increased 82% since the drug launched in 2013. Outside of the U.S., the cost of Humira has fallen in recent years.

“AbbVie pursued a variety of tactics to increase drug sales while raising prices for Americans, including exploiting the patent system to extend it…

10 of the best pharma companies to work for

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research.

The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries.

To get a sense of which pharmaceutical companies in the sector were the best employers, we sifted through data on company reviews sites Glassdoor and Comparably, and other sources.

Here are the 10 companies that came in on top:

Get the full story from our sister site, Drug Discovery & Development.

10 of the best pharma companies to work for

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research.

The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries.

To get a sense of which pharmaceutical companies in the sector were the best employers, we sifted through data on company reviews sites Glassdoor and Comparably, and other sources.

Here are the 10 companies that came in on top.

Get the full story from our sister site, Drug Discovery & Development.

And browse data on all the Pharma 50 companies here.

10 of the best pharma companies to work for

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research.

The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries.

To get a sense of which pharmaceutical companies in the sector were the best employers, we sifted through data on company reviews sites Glassdoor and Comparably, and other sources.

Below are the 10 companies that came in on top. (And browse data on all the Pharma 50 companies here.)

1. Sage Therapeutics

Glassdoor rating: 4.4/5 83% would recommend to a friend

Pros: Workers at Sage Therapeutics applauded the company’s work-life balance and culture. Just under three-quarters (74%) had a positive business outlook for the firm. One recent reviewer found meaning in “doing the toughest job in the world by developing CNS drugs.” The company’s brain health p…

FDA approves Janssen’s Rybrevant for subset of non-small cell lung cancer

Rybrevant, a novel fully-human bispecific antibody from the Janssen division of Johnson & Johnson, became the first treatment for people with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. In particular, the indication covers such cancer that has progressed on or after platinum-based chemotherapy.

The agency also approved the Guardant360 CDx from Guardant Health as a companion diagnostic for Rybrevant.

“Advances in precision oncology continue to facilitate drug development, allowing diseases like lung cancer to be subset into biomarker-defined populations appropriate for targeted therapies,” said Dr. Julia Beaver, chief of medical oncology in the FDA’s Oncology Center of Excellence, in a statement. “With today’s approval, for the first time, patients with non-small cell lung cancer with EGFR exon 20 insertion mutations will have a targeted treatment option.”

[Related: 25 promising pipeline drugs]<…

Pharma’s top 20 R&D spenders in 2020

[Lab image by Michal Jarmoluk from Pixabay]The past year has been an unprecedented time for the pharmaceutical industry.

On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.

While the pandemic certainly was a driver for substantial R&D spending in the industry in 2020, a significant expense for many companies last year was licensing fees and other acquisition costs. That trend is not just apparent for Incyte, which tops this list, but also for several other companies in this ranking of 20 firms, which are ranked below based on the percent of revenue they invest in R&D. (To find out the top 50 pharma companies, check out our recently published ranking here.)

Get the full picture from our sister site, Drug Discovery & Development.

Pharma’s top 20 R&D spenders in 2020

[Lab image by Michal Jarmoluk from Pixabay]

The past year has been an unprecedented time for the pharmaceutical industry.

On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.

While the pandemic certainly was a driver for substantial R&D spending in the industry in 2020, a significant expense for many companies last year was licensing fees and other acquisition costs. That trend is not just apparent for Incyte, which tops this list, but also for several other companies in this ranking of 20 firms, which are ranked below based on the percent of revenue they invest in R&D. (To find out the top 50 pharma companies, check out our recently published ranking here.)

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies also overcame COVID-19-related clinical trial disruption and staffing hurdles, driving unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

One of the most notable achievements involved the mRNA vaccines from Pfizer/BioNTech and Moderna, according to analyst Mani Foroohar at SVB Leerink.

Other achievements, according to Foroohar, includ…

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.

FDA, CDC lift pause on J&J COVID-19 vaccine

The FDA and CDC have lifted the pause placed on the Johnson & Johnson (NYSE:JNJ) COVID-19 vaccine after reports of blood clots caused concern.

On April 13, the FDA and CDC issued a joint statement recommending the pause in the administration of the J&J (Janssen) COVID-19 vaccine after, among 6.8 million doses delivered in the U.S., six recipients experienced cases of a rare and severe type of blood clot. Of those blood clot cases, one death was recorded.

Following a safety review that included two meetings of the CDC’s Advisory Committee on Immunization Practices, the pause was lifted on Friday, April 23, according to a news release Medical and scientific teams at the FDA and CDC examined available data to evaluate the risk of the form of blood clot known as cerebral venous sinus thrombosis (CVST) that was seen in combination with low levels of blood platelets (thrombocytopenia).

The two agencies concluded that use of the vaccine can resume…